Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


The company landscape for artificial intelligence in large-molecule drug discovery

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 22, 949-950 (2023)



The authors wish to thank Jeffrey Algazy, Joachim Bleys, Sam White, Ester Friedlaenderova, Thomas Devenyns, Rachel Moss, Michael Steinmann and Chris Anagnostopoulos for their contributions to this article.

Supplementary Information

  1. Supplementary information

Competing Interests

The authors of this article are employees of McKinsey & Company, a management consultancy that works with the world’s leading biopharmaceutical and biotechnology companies. The research for this specific article was funded by McKinsey’s Life Sciences practice.

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links